INTRODUCTION
Environmentally exposed surfaces in humans and other multicellular organisms are colonized by a vast number of microbes, collectively referred to as the commensal microbiota (
1,
2). Humans are home to approximately 10
13 to 10
14 commensal bacteria, with the preponderance of these located in the gastrointestinal tract (
3). The long evolutionary relationship between host and commensal microbiota means that these indigenous organisms influence many aspects of host physiology. Their importance has been demonstrated in numerous clinical studies and by using animal models, which show that disruption of host-commensal interactions is associated with a variety of diseases and conditions (
1,
2,
4–14). These include cancer (
8), chronic intestinal inflammation (
12,
15), autoimmunity (
14), and increased susceptibility to infection by bacteria, viruses, and parasites, both in the intestine and at extraintestinal sites (
1,
4,
16–24). An underlying principal emerging from these studies is that the commensal microbiota is a major regulator of host immune function, and it is the disruption of this interaction that underlies many of these conditions. Therefore, understanding the interaction of the commensal microbiota and immune system is of major importance.
Given that the preponderance of commensal bacteria reside on the intestinal mucosa, most studies have focused on understanding how the microbiota regulates immunity at this site. This work has revealed that at the intestinal mucosa, pattern recognition receptors (PRRs) of the innate immune system are constantly engaged by the microbiota, and that this promotes maturation of the intestinal immune system and maintains intestinal homeostasis (
12,
25). The adaptive immune system in the intestine is also regulated by the microbiota, with specific groups of commensal bacteria promoting the development of effector and regulatory T-cell populations (
2). This includes induction of T
H17 cells that fortify the mucosal barrier (
26) and T
REG cells that dampen immune responses to prevent chronic inflammation (
27,
28). Colonization by the microbiota also helps protect against intestinal infection. This occurs via numerous mechanisms, including the direct production of inhibitory molecules and depletion of nutrients by the microbiota to prevent the establishment of colonization and growth of potential pathogens (
29–31). Additionally, the intestinal microbiota stimulates local innate production of antimicrobial peptides via PRRs to promote the killing of intestinal pathogens (
17). Therefore, the commensal microbiota is crucial for optimal immune responses to intestinal pathogens.
In contrast, our understanding of how the commensal microbiota regulates immunity to infection at sites outside the intestine remains limited. The regulation of antiviral immunity at extraintestinal sites is perhaps the best characterized (
32). Numerous studies have shown that in the absence of signals from commensal bacteria, the host is more susceptible to systemic and pulmonary viral infection (
16,
22,
33). This has been ascribed to defects in the production of interferon by the innate immune system (
16,
22) and reduced CD4
+ and CD8
+ T-cell generation during the adaptive antiviral response (
33). Furthermore, the skin microbiota helps generate adaptive immune responses to protect against cutaneous infection by the parasite
Leishmania major (
11). Currently, and in contrast to other classes of pathogens, the understanding of how the microbiota regulates antibacterial immunity at extraintestinal sites is poor. It is known that in the absence of signals from commensal bacteria, mice more easily succumb to infection by a variety of bacterial pathogens, including
Listeria monocytogenes and
Klebsiella pneumoniae (
9,
21,
23). Furthermore, it is known that killing of
Streptococcus pneumoniae and
Staphylococcus aureus by neutrophils from microbiota-depleted mice
ex vivo is reduced (
34). Therefore, currently it is broadly understood that the commensal microbiota helps protect against bacterial infection outside the intestine (
9). What remain to be determined are the precise components of antibacterial immunity enhanced by the commensal microbiota and the demonstration that these components mediate protection against bacterial infection
in vivo. Also, the nature of the signals that enhance extraintestinal antibacterial immunity and the origin of these signals need to be established. In this study, using a variety of
in vivo and
ex vivo models, I show that early defenses against respiratory infection by
K. pneumoniae, a major lung pathogen, especially in patients receiving long-term antibiotic therapy, are enhanced by bacterial peptidoglycan. These cell wall components, recognized by the Nod-like receptors (NLRs) NOD1 and NOD2, originated from the intestine and enhanced the production of reactive oxygen species (ROS) in alveolar macrophages. Consequently, there was increased bacterial killing by these cells, and this was required to facilitate early bacterial clearance from the lung.
DISCUSSION
Macrophages and neutrophils provide an effective way for the host to rapidly deploy powerful antimicrobial effectors, such as proteases, antimicrobial peptides, and reactive oxygen species, in a targeted manner to control infection and maintain tissue homeostasis (
56). These antimicrobial effectors, however, come at a cost, both in the energetic input required for their production and mobilization and also because they act indiscriminately and can be extremely damaging to host tissues (
57,
58). Thus, an appropriate immune set-point must be established with adequate production, deployment, and functioning of innate cells to facilitate control of a given pathogenic threat without damaging exuberance and profligate use of resources. An implicit assumption made when considering innate immunity and inflammation has been that the host is the major regulator that establishes this set-point (
56,
59), and that microbial influences on this are restricted to fine-tuning innate cell function locally in the vicinity of the mucosa (
60). It is now becoming apparent that this localized view is incorrect and that commensal microbes in the intestine exert a systemic influence on effector cells of the innate immune system at extraintestinal sites, and that this contributes to the establishment of the innate immune set-point (
8,
16,
22,
33,
34). The mechanistic basis for these distal influences, the precise cellular functions in innate cells regulated systemically by commensal bacteria, and the impact this has on host defenses to bacterial infection outside the intestine have been incompletely characterized. Previous studies have shown increased mortality from bacterial infection in the lung in the absence of the microbiota (
21,
61), but the specific immune defects that cause this are poorly understood. Data presented here show that the antibacterial activity of alveolar macrophages is compromised in the absence of the commensal microbiota, leading to defects in early bacterial clearance from the lung, which can be restored by administration of bacterial NLR ligands via the gastrointestinal tract. This builds on previous work showing that microbiota-derived NOD1 ligands enhance the antibacterial activity of neutrophils in bone marrow (
34). Furthermore, in this study and in contrast to previous work (
34), I was able to show that the antibacterial effector mechanism enhanced by the microbiota and required for efficient clearance of bacteria from the lung was the production of reactive oxygen species in alveolar macrophages.
Alveolar macrophages are key sentinels that constantly patrol and monitor lung tissue (
51,
52). These cells are long-lived, with approximately 40% of alveolar macrophages replaced per year in a healthy murine lung, and are the first line of defense against respiratory pathogens (
62). Tissue-specific cues ensure alveolar macrophages are ideally suited to their role in the lung; however, local reprogramming in response to chronic inflammation or infection allows adaptation to environmental changes (
62). For example, after the resolution of lung infection by influenza, alveolar macrophages undergo enduring changes, producing reduced levels of inflammatory cytokines and increased levels of anti-inflammatory cytokines, such as IL-10, when restimulated by TLR ligands after infection (
19). Data from the current study show that, in addition to local signals, the antibacterial activity of alveolar macrophages is programmed systemically by signals from the intestine. This systemic effect of intestine-derived signals on lung function fits with recent work showing that shifts in the composition of the intestinal microbiota cause changes in alveolar macrophages that increase allergic inflammation in the airway (
41). The role of pattern recognition receptors was not investigated in that study, and changes in alveolar macrophage function were shown to be due to increased prostaglandin E
2 levels in the circulation (
41). Additionally, another study has shown that defects in migration to draining lymph nodes and reduced production of IL-1β by lung dendritic cells lead to reduced adaptive immune responses to influenza virus infection after microbiota depletion, and that this could be corrected by intrarectal administration of TLR ligands (
33).
The importance of lung integrity for gaseous exchange means that the production of inflammatory mediators and any molecule that could cause tissue damage by alveolar macrophages is severely restrained. Reactive oxygen species are a crucial antibacterial effector mechanism in the lung, but as they act nonspecifically, they have the potential to cause significant damage. Thus, a variety of detoxification mechanisms operate to mitigate their deleterious effects (
63). Data presented here show that in addition to detoxification, the host meters the production of reactive oxygen species in response to microbiota-derived signals. This supports a model of host defense whereby the levels of ROS production are continually gauged to facilitate host control of bacteria, whether they are commensal bacteria at the mucosa or acquired pathogens that gain entry into normally sterile tissues or tissues that can tolerate only a very small number of bacteria, such as the lung, while minimizing ROS production and concomitant tissue damage. Taken together, previous studies (
19,
62) and data presented here show that macrophages in the lung assimilate information from various local and systemic cues and modify their function accordingly in order to maintain tissue homeostasis while maximizing local host defenses. As lung infection remains a major cause of mortality worldwide, this underappreciated flexibility is of significant therapeutic potential, as it may be possible to reprogram lung defenses to improve immune responses to clear infection.
The localized influence of commensal bacteria on immunity to infection at the barrier site they colonize is increasingly well characterized, especially in the intestine. Outside the intestine, it has also been shown that skin commensals regulate local T-cell-mediated immunity to cutaneous
Leishmania major infection via IL-1 signaling (
11), and upper airway commensals regulate immunity to viral infection in the lower airway (
42). Furthermore, studies have also shown that repeated intranasal administration of a combination of both bacterial and fungal ligands to mice colonized by commensal bacteria provides additional local stimulation that enhances survival during bacterial lung infection (
64). In the current study, defects in bacterial clearance from the lung due to microbiota depletion could be rescued only by NLR ligands originating from the intestine and not the upper airway. This suggests that under basal conditions the intestinal microbiota, not the airway microbiota, play a dominant role in establishing the levels of early antibacterial immunity in the lung. Furthermore, it shows that commensal bacteria at one barrier site can regulate antibacterial immunity at another, distal barrier site. As the current study focused on the very immediate response to infection, this does not preclude the possibility that the upper airway microbiota, or TLR ligands, regulate other aspects of lung immunity important at later time points during infection. For example, other studies have shown that in the absence of signals from the microbiota, there is increased mortality during bacterial lung infection, and this could be rescued by LPS administration either in the drinking water or via intraperitoneal injection (
21,
61). These studies analyzed later time points in infection than this study and did not address the role of NLRs, but they do raise the possibility that TLR ligands regulate other components of lung immunity important during the later stages in lung infection. Further work to understand how immunity at one barrier site is programmed by signals from both proximal and distal commensal populations is required to address this. The mechanistic basis as to why early bacterial clearance in the lung could be rescued only by NLR ligands from the intestine and not the upper airway currently is unclear but no doubt reflects the central role the intestinal microbiota has evolved to play in regulating the immune system. One possible explanation is the requirement of an intermediate signal between commensal stimulation of NLRs in the intestine and enhanced macrophage function in the airway. In contrast to TLRs, whose activation is tightly restrained in the intestine (
65), NLRs are expressed in the intestinal mucosa and are activated by resident commensals (
66), and this could result in the production of a signal originating from the intestinal mucosa that has a systemic effect on host lung function. Alternatively, peptidoglycan from the intestinal microbiota is found systemically in nonmucosal tissues of healthy mice and humans (including blood, spleen, and bone marrow) (
34,
49,
50), and this disseminated peptidoglycan may activate underlying lung tissue to regulate alveolar macrophage function.
The priming of alveolar macrophage function in the lung and neutrophil function in the bone marrow via recognition of microbiota-derived peptidoglycan by NLRs is part of a wider phenomenon of immune recognition of PRR ligands under homeostatic conditions. PRRs originally were thought to sense the presence of infectious microbes and promote pathogen clearance (
67), but data from this study and numerous others (
16,
22,
25,
33,
34,
68,
69) show basal activation of PRRs by the microbiota in both mucosal and nonmucosal tissues in the absence of infection. This is important for the development of the immune system (
6,
13), facilitates colonization by the commensal microbiota (
69), prevents chronic inflammation (
25), and enhances killing of pathogens by innate cells (
34). Recent studies also have shown that basal stimulation of the innate immune system by the microbiota via PRRs and their ligands promotes hematopoiesis (
18,
24), increasing the number of circulating neutrophils and macrophages. This helps protect against bacterial sepsis. In the current study, neutrophils played no role in microbiota-mediated enhancement of bacterial clearance from the lung and the amount of macrophages in the lung also was unchanged after microbiota depletion, probably a reflection of the low turnover rate of these cells in lung tissue (
62). Enhanced clearance of bacteria from the lung did, however, depend on increased ROS production by alveolar macrophages via microbiota stimulation. Thus, in this study, functional reprogramming of innate cells was found to be important for enhanced innate immunity to bacterial infection rather than increased innate cell production. All of these studies fit with recent reevaluations of PRR function, positing that they play a more nuanced role in host physiology, acting as regulators of immune homeostasis and not purely as sensors of infection (
6).
Much remains to be understood about the systemic influence of commensal bacteria on host defense against infection. The continued worldwide mortality caused by bacterial infection means that the widespread use of antibiotics will continue. However, in addition to increasing antibiotic resistance, antibiotic-mediated microbiota disruption could lead to increased susceptibility to bacterial infection because of the profound importance of commensal stimulation for innate responses to pathogens (
4). Because of this, it is important to delineate whether all microbial groups within the microbiota are equal in their ability to program innate cell function to be able to develop therapeutic strategies that avoid those that are important for stimulating the antibacterial activity of innate cells. Furthermore, the wide-ranging influence of the commensal microbiota on the innate response to bacterial infection suggests that adaptive immunity to bacterial pathogens at extraintestinal sites will be similarly influenced. Deciphering the mechanistic basis for these effects could be of tremendous utility in the fight against infectious disease, as it could suggest novel strategies to enhance immune responses elicited by vaccines.